Prascend (Pergolide Mesylate) Tablets
MFR
Boehringer Ingelheim
Pergolide mesylate, a dopamine receptor agonist for oral use in horses.
SKU
039712
$212.99
Pergolide mesylate (1 mg tablets), a dopamine receptor agonist for oral use in horses. This is the first and only FDA-approved treatment for the control of clinical signs associated with Pituitary Pars Intermedia Dysfunction (Equine Cushing’s Disease) in horses. Do not use in horses intended for human consumption. May interfere with reproductive hormones and events in breeding, pregnant, or lactating horses.
| Directions | Administer orally at a starting dose of 2.0 µg/kg once daily. Dosage may be adjusted to effect, not to exceed 4.0 µg/kg daily. Prascend Tablets should not be crushed due to the potential for increased human exposure.
The tablets are scored and the calculated dosage should be provided to the nearest one-half tablet increment.
Dosing should be titrated according to individual response to therapy to achieve the lowest effective dose. Dose titration is based on improvement in clinical signs associated with Pituitary Pars Intermedia Dysfunction (PPID) and/or improvement or normalization of endocrine tests (for example, dexamethasone suppression test or endogenous ACTH test). If signs of dose intolerance develop, the dose should be decreased by half for 3 to 5 days and then titrated back up in 2 mcg/kg increments every 2 weeks until the desired effect is achieved. |
|---|
Write Your Own Review
There are no any videos in this product.
My Wish List
Last Added Items
You have no items in your wish list.
